Cheng-Kuan Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cheng-Kuan Lin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Chen-Shuan Chung
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan
3 shared publications - Tzong-Hsi Lee
Division of Gastroenterology and Hepatology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
3 shared publications - Chen-Yen Lu
From the Division of Gastroenterology and Hepatology, Department of Internal Medicine (C.Y.L., P.C.T., K.C.C., T.H.L., C.K.L., C.S.C.), and Department of Radiology (C.C.H., Y.M.T.), Far Eastern Memorial Hospital, 21 Nan-Ya South Rd, Section 2, Banciao District, New Taipei City, Taiwan 22060; and College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan (C.S.C.).
2 shared publications - Chun-Chieh Huang
Division of Medical Imaging, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan
2 shared publications - Chung-Tsui Huang
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Far Eastern Memorial Hospital, New Taipei, Taiwan
2 shared publications Kuan-Chih Chen
From the Division of Gastroenterology and Hepatology, Department of Internal Medicine (C.Y.L., P.C.T., K.C.C., T.H.L., C.K.L., C.S.C.), and Department of Radiology (C.C.H., Y.M.T.), Far Eastern Memorial Hospital, 21 Nan-Ya South Rd, Section 2, Banciao District, New Taipei City, Taiwan 22060; and College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan (C.S.C.).
2 shared publications
Latest Publications
- Open Access
- 10 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0333940
Differences among specialists in using the Electronic Medical Record alert system for HCV screening in outpatients at a large general hospital
Background & objectives: Some hepatitis C virus (HCV) patients remain underdiagnosed at a large hospital. The electronic medical record (EMR) alert system can increase in-hospital screening. This study evaluates the effectiveness of screening among outpatients and assesses variations in physician engagement across different specialties. Methods: From December 2022 to April 2023, outpatients aged 45–79 years, with diabetes mellitus or chronic kidney disease, who did not have anti-HCV data in their EMR were identified. A pop-up alert prompted physicians to either order anti-HCV testing or refer patients for a health check-up. The frequency of alerts, physician response rates, blood test completion rates, and HCV seropositivity were analyzed by specialty. Results: Of 85,320 alerts generated, 61.4% elicited a physician response. Internal Medicine clinics had significantly higher response rates than non-Internal Medicine clinics (77.5% versus 44.6%, P < 0.01). Among patients with physician responses, 30.9% completed the study, with markedly higher completion when blood tests were directly ordered compared to referrals (88.4% versus 7.2%, P < 0.01). The monthly number of screenings increased tenfold after the system was implemented. Overall, 22,377 patients (26.2%) were screened, and 485 (2.17%) were seropositive. One-fourth of seropositive cases were identified in non-Internal Medicine clinics, where the positivity rate was higher (2.7% versus 2.04%, P = 0.01). Conclusions: Short-term use of the EMR alert system increased HCV detection among outpatients. The default test orders in the EMR improved completion rates more than referrals to a health check-up. There were differences in physician engagement and seropositive case detection among specialties. Targeted interventions, particularly among specialties with lower engagement, are necessary to improve the success of HCV screening.
- 10 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0333940
Open AccessDifferences among specialists in using the Electronic Medical Record alert system for HCV screening in outpatients at a large general hospital
Background & objectives: Some hepatitis C virus (HCV) patients remain underdiagnosed at a large hospital. The electronic medical record (EMR) alert system can increase in-hospital screening. This study evaluates the effectiveness of screening among outpatients and assesses variations in physician engagement across different specialties. Methods: From December 2022 to April 2023, outpatients aged 45–79 years, with diabetes mellitus or chronic kidney disease, who did not have anti-HCV data in their EMR were identified. A pop-up alert prompted physicians to either order anti-HCV testing or refer patients for a health check-up. The frequency of alerts, physician response rates, blood test completion rates, and HCV seropositivity were analyzed by specialty. Results: Of 85,320 alerts generated, 61.4% elicited a physician response. Internal Medicine clinics had significantly higher response rates than non-Internal Medicine clinics (77.5% versus 44.6%, P < 0.01). Among patients with physician responses, 30.9% completed the study, with markedly higher completion when blood tests were directly ordered compared to referrals (88.4% versus 7.2%, P < 0.01). The monthly number of screenings increased tenfold after the system was implemented. Overall, 22,377 patients (26.2%) were screened, and 485 (2.17%) were seropositive. One-fourth of seropositive cases were identified in non-Internal Medicine clinics, where the positivity rate was higher (2.7% versus 2.04%, P = 0.01). Conclusions: Short-term use of the EMR alert system increased HCV detection among outpatients. The default test orders in the EMR improved completion rates more than referrals to a health check-up. There were differences in physician engagement and seropositive case detection among specialties. Targeted interventions, particularly among specialties with lower engagement, are necessary to improve the success of HCV screening.
- Open Access
- 2 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 32312
Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk
The elevation of serum alpha-fetoprotein (AFP) is frequently observed in patients with chronic hepatitis C (CHC). In most cases, the level decreased after antiviral treatment. This study investigated the relationship between post-treatment AFP normalization and the risk of hepatocellular carcinoma (HCC) in CHC patients without baseline HCC. A total of 483 patients treated with sofosbuvir-based direct-acting antivirals (DAAs) were enrolled and followed for a mean duration of 38.8 months. The mean age was 59.6 years, and 27.1% of patients had liver cirrhosis. The sustained virological response (SVR) rate was 98.6%. The pre-treatment AFP levels > 7 ng/mL, > 10 ng/mL, and > 15 ng/mL were observed in 25.4%, 18.8%, and 9.7% of patients, respectively. By 12 weeks post-treatment, 86.2% of patients had AFP levels < 7 ng/mL. During follow-up, 5.4% of patients developed HCC. The independent risk factors for HCC included age ≥ 65 years, liver cirrhosis, and post-treatment AFP > 7 ng/mL. The hazard ratio of HCC was 0.03 (95% CI: 0.01-0.3, P < 0.01) in the "Normalization" group, compared to the "Persistent elevation" group. The hazard ratio was 0.28 (95% CI: 0.1-0.73, P = 0.01) in the "Stable normal" group, compared to the "Elevation" group. The findings suggest that normalization of AFP levels or stable normal levels after treatment are associated with a reduced risk of HCC.
- 2 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 32312
Open AccessNormalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk
The elevation of serum alpha-fetoprotein (AFP) is frequently observed in patients with chronic hepatitis C (CHC). In most cases, the level decreased after antiviral treatment. This study investigated the relationship between post-treatment AFP normalization and the risk of hepatocellular carcinoma (HCC) in CHC patients without baseline HCC. A total of 483 patients treated with sofosbuvir-based direct-acting antivirals (DAAs) were enrolled and followed for a mean duration of 38.8 months. The mean age was 59.6 years, and 27.1% of patients had liver cirrhosis. The sustained virological response (SVR) rate was 98.6%. The pre-treatment AFP levels > 7 ng/mL, > 10 ng/mL, and > 15 ng/mL were observed in 25.4%, 18.8%, and 9.7% of patients, respectively. By 12 weeks post-treatment, 86.2% of patients had AFP levels < 7 ng/mL. During follow-up, 5.4% of patients developed HCC. The independent risk factors for HCC included age ≥ 65 years, liver cirrhosis, and post-treatment AFP > 7 ng/mL. The hazard ratio of HCC was 0.03 (95% CI: 0.01-0.3, P < 0.01) in the "Normalization" group, compared to the "Persistent elevation" group. The hazard ratio was 0.28 (95% CI: 0.1-0.73, P = 0.01) in the "Stable normal" group, compared to the "Elevation" group. The findings suggest that normalization of AFP levels or stable normal levels after treatment are associated with a reduced risk of HCC.
- Open Access
- 18 October 2024
- Published by Springer Nature in Psicologia: Reflexão e Crítica
- Vol. 37 (1) , 1-12
The Gaming Disorder Test and Gaming Disorder Scale for Adolescents: Translation and validation among Vietnamese young adults
Background: Previous studies have shown that the Gaming Disorder Test (GDT) and Gaming Disorder Scale for Adolescents (GADIS-A) have promising validity and reliability when assessing symptoms of gaming disorder among young adults. However, validity and reliability properties of the two scales have not been established among a Vietnamese population. Objective: The present study translated the GDT and GADIS-A into Vietnamese and examined their factor structures, measurement invariance, convergent validity, concurrent validity, and divergent validity among university students. Methods: A total of 610 young adults (mean age = 21.09 years; 63.4% females) were recruited using convenience sampling and who completed a paper-and-pencil survey between April and June 2023. All participants completed a demographic questionnaire, GDT, GADIS-A, and six standardized scales related to gaming disorder, social media addiction, smartphone addiction, and psychological distress. Confirmatory factor analysis (CFA), internal consistency testing, and Pearson’s correlations were performed. Results: CFA showed that the GDT had a one-factor structure and the GADIS-A had a two-factor structure. The internal consistency was excellent for both scales among this population. Moreover, both GDT and GADIS-A showed convergent, concurrent, and divergent validity with other standardized scales. Conclusion: The Vietnamese versions of the GDT and GADIS-A have good psychometrics, which may be utilized in future research regarding gaming disorder among Vietnamese populations.
- 18 October 2024
- Published by Springer Nature in Psicologia: Reflexão e Crítica
- Vol. 37 (1) , 1-12
Open AccessThe Gaming Disorder Test and Gaming Disorder Scale for Adolescents: Translation and validation among Vietnamese young adults
Background: Previous studies have shown that the Gaming Disorder Test (GDT) and Gaming Disorder Scale for Adolescents (GADIS-A) have promising validity and reliability when assessing symptoms of gaming disorder among young adults. However, validity and reliability properties of the two scales have not been established among a Vietnamese population. Objective: The present study translated the GDT and GADIS-A into Vietnamese and examined their factor structures, measurement invariance, convergent validity, concurrent validity, and divergent validity among university students. Methods: A total of 610 young adults (mean age = 21.09 years; 63.4% females) were recruited using convenience sampling and who completed a paper-and-pencil survey between April and June 2023. All participants completed a demographic questionnaire, GDT, GADIS-A, and six standardized scales related to gaming disorder, social media addiction, smartphone addiction, and psychological distress. Confirmatory factor analysis (CFA), internal consistency testing, and Pearson’s correlations were performed. Results: CFA showed that the GDT had a one-factor structure and the GADIS-A had a two-factor structure. The internal consistency was excellent for both scales among this population. Moreover, both GDT and GADIS-A showed convergent, concurrent, and divergent validity with other standardized scales. Conclusion: The Vietnamese versions of the GDT and GADIS-A have good psychometrics, which may be utilized in future research regarding gaming disorder among Vietnamese populations.
- Open Access
- 26 July 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 676-677
Endoscopic mucosal resection with a ligation device for rectal subepithelial tumors: A case series
- 26 July 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 676-677
Open AccessEndoscopic mucosal resection with a ligation device for rectal subepithelial tumors: A case series
- Open Access
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35922
Cardiac events after using clarithromycin for anti-Helicobacter pylori therapy in patients with coronary artery disease
Clarithromycin is an antibiotic commonly used to treat Helicobacter pylori infections. The US Food and Drug Administration (FDA) advises caution before prescribing clarithromycin to patients with cardiac diseases. This study aimed to evaluate cardiac events after anti-H pylori treatment in patients with coronary artery disease. A retrospective 5-year study was conducted on outpatients who received anti-H pylori therapy. Among the 7855 patients receiving therapy, 228 patients (2.9%) underwent angiography with coronary artery disease before therapy, and 193 patients received clarithromycin. Clarithromycin users seemed not to be at risk for cardiac events as compared with non-clarithromycin users at 3 months (4.7% vs 2.9%, P = .63) and 1 year (10.9% vs 5.7%, P = .35). Neither life-threatening dysrhythmia nor cardiac death was noted. The risk factors for cardiac events within 3 months after therapy were smoker (OR:5.38, 95% CI:1.39–20.78), and events within 1 year were smoker (OR:3.8, 95% CI:1.41–10.22), and diabetes mellitus (OR:5.68, 95% CI:1.9–16.98). Among patients with coronary artery disease who received anti-H pylori therapy, short-term cardiac events did not increase in clarithromycin users but should be considered in diabetic and smoking patients.
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35922
Open AccessCardiac events after using clarithromycin for anti-Helicobacter pylori therapy in patients with coronary artery disease
Clarithromycin is an antibiotic commonly used to treat Helicobacter pylori infections. The US Food and Drug Administration (FDA) advises caution before prescribing clarithromycin to patients with cardiac diseases. This study aimed to evaluate cardiac events after anti-H pylori treatment in patients with coronary artery disease. A retrospective 5-year study was conducted on outpatients who received anti-H pylori therapy. Among the 7855 patients receiving therapy, 228 patients (2.9%) underwent angiography with coronary artery disease before therapy, and 193 patients received clarithromycin. Clarithromycin users seemed not to be at risk for cardiac events as compared with non-clarithromycin users at 3 months (4.7% vs 2.9%, P = .63) and 1 year (10.9% vs 5.7%, P = .35). Neither life-threatening dysrhythmia nor cardiac death was noted. The risk factors for cardiac events within 3 months after therapy were smoker (OR:5.38, 95% CI:1.39–20.78), and events within 1 year were smoker (OR:3.8, 95% CI:1.41–10.22), and diabetes mellitus (OR:5.68, 95% CI:1.9–16.98). Among patients with coronary artery disease who received anti-H pylori therapy, short-term cardiac events did not increase in clarithromycin users but should be considered in diabetic and smoking patients.
- Open Access
- 9 February 2022
- Published by Wiley in Advances in Digestive Medicine
- Vol. 10 (1) , 46-49
Gastric amyloidosis associated with multiple myeloma: A rare cause of upper gastrointestinal bleeding
- 9 February 2022
- Published by Wiley in Advances in Digestive Medicine
- Vol. 10 (1) , 46-49
Open AccessGastric amyloidosis associated with multiple myeloma: A rare cause of upper gastrointestinal bleeding
- 1 December 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 301 (3) , 735-740
Case 296: Phlebosclerotic Colitis
History A 55-year-old woman without systemic underlying disease, such as diabetes mellitus, inflammatory bowel disease, autoimmune disease, or chronic kidney disease, presented with generalized dul...
- 1 December 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 301 (3) , 735-740
Case 296: Phlebosclerotic Colitis
History A 55-year-old woman without systemic underlying disease, such as diabetes mellitus, inflammatory bowel disease, autoimmune disease, or chronic kidney disease, presented with generalized dul...
- 1 August 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 300 (2) , 481-483
Case 296
History A 55-year-old woman without systemic underlying disease, such as diabetes mellitus, inflammatory bowel disease, autoimmune disease, or chronic kidney disease, presented with generalized dull abdominal pain of 1-week duration. She had ingested herbal medicine for physical conditioning for several years. Laboratory findings, including biochemistry, electrolyte levels, and complete blood count, were all within normal limits, except for elevated serum C-reactive protein level (7.719 mg/dL; normal range,<1 mg/dL). The patient underwent initial evaluation with conventional abdominal radiography (Fig 1). She underwent subsequent evaluation with noncontrast CT of the abdomen (Figs 2, 3) and colonoscopy (Fig 4).
- 1 August 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 300 (2) , 481-483
Case 296
History A 55-year-old woman without systemic underlying disease, such as diabetes mellitus, inflammatory bowel disease, autoimmune disease, or chronic kidney disease, presented with generalized dull abdominal pain of 1-week duration. She had ingested herbal medicine for physical conditioning for several years. Laboratory findings, including biochemistry, electrolyte levels, and complete blood count, were all within normal limits, except for elevated serum C-reactive protein level (7.719 mg/dL; normal range,<1 mg/dL). The patient underwent initial evaluation with conventional abdominal radiography (Fig 1). She underwent subsequent evaluation with noncontrast CT of the abdomen (Figs 2, 3) and colonoscopy (Fig 4).
- Open Access
- 13 July 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (7) , 1252
Pancreatic Fibrosis (Early Chronic Pancreatitis) as Emerging Diagnosis in Structural Causes of Dyspepsia: Evidence from Endoscopic Ultrasonography and Shear Wave Elastography
A new concept for the diagnosis and management of non-functional dyspepsia in guidelines was lacking in the past decade. Medical advancement has proven pancreatic fibrosis (essential image evidence of early chronic pancreatitis) to be a cause of dyspepsia and related to pancreatic exocrine dysfunction. This study aimed to analyze the clinical picture, biomarker, and percentage of pancreatic fibrosis in the dyspeptic population. A total of 141 consecutive patients were retrospectively enrolled. They were diagnosed with peptic ulcer disease, 9.2% (n = 13); pancreatic fibrosis, 17% (n = 24); pure Helicobacter pylori infection, 19.9% (n = 28); functional dyspepsia, 53.2% (n = 75); and chronic pancreatitis, 0.7% (n = 1). Among those with pancreatic fibrosis, (n = 24), 11 were diagnosed on the basis of a pancreatic acoustic radiation force impulse exceeding 1.4 m/s, and the remaining 13 were diagnosed with early chronic pancreatitis with at least three of the Japanese endoscopic ultrasonography criteria. The anatomic distribution of parenchymal criteria of early chronic pancreatitis was head, 53%; body, 38%; and tail, 9%. There were 17 cases (71%, 17/24) without Helicobacter pylori and whose dyspepsia improved after pancreatic enzyme replacement with a ratio of 82.3% (14/17). Of the 141 cases, 19 received gastric emptying scintigraphy and Western blot analysis of chromogranin-A in duodenal mucosa. Delayed gastric emptying was more common in functional dyspepsia and chromogranin-A was expressed more in pancreatic fibrosis. In conclusion, pancreatic fibrosis (including early chronic pancreatitis) outnumbered peptic ulcer disease in the dyspeptic population and pancreatic enzyme therapy was effective for 82% of cases. In early chronic pancreatitis, pancreatic fibrosis is dominant in the head location, and duodenum mucosa chromogranin-A is a potential biomarker with increased expression in an age-matched manner.
- 13 July 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (7) , 1252
Open AccessPancreatic Fibrosis (Early Chronic Pancreatitis) as Emerging Diagnosis in Structural Causes of Dyspepsia: Evidence from Endoscopic Ultrasonography and Shear Wave Elastography
A new concept for the diagnosis and management of non-functional dyspepsia in guidelines was lacking in the past decade. Medical advancement has proven pancreatic fibrosis (essential image evidence of early chronic pancreatitis) to be a cause of dyspepsia and related to pancreatic exocrine dysfunction. This study aimed to analyze the clinical picture, biomarker, and percentage of pancreatic fibrosis in the dyspeptic population. A total of 141 consecutive patients were retrospectively enrolled. They were diagnosed with peptic ulcer disease, 9.2% (n = 13); pancreatic fibrosis, 17% (n = 24); pure Helicobacter pylori infection, 19.9% (n = 28); functional dyspepsia, 53.2% (n = 75); and chronic pancreatitis, 0.7% (n = 1). Among those with pancreatic fibrosis, (n = 24), 11 were diagnosed on the basis of a pancreatic acoustic radiation force impulse exceeding 1.4 m/s, and the remaining 13 were diagnosed with early chronic pancreatitis with at least three of the Japanese endoscopic ultrasonography criteria. The anatomic distribution of parenchymal criteria of early chronic pancreatitis was head, 53%; body, 38%; and tail, 9%. There were 17 cases (71%, 17/24) without Helicobacter pylori and whose dyspepsia improved after pancreatic enzyme replacement with a ratio of 82.3% (14/17). Of the 141 cases, 19 received gastric emptying scintigraphy and Western blot analysis of chromogranin-A in duodenal mucosa. Delayed gastric emptying was more common in functional dyspepsia and chromogranin-A was expressed more in pancreatic fibrosis. In conclusion, pancreatic fibrosis (including early chronic pancreatitis) outnumbered peptic ulcer disease in the dyspeptic population and pancreatic enzyme therapy was effective for 82% of cases. In early chronic pancreatitis, pancreatic fibrosis is dominant in the head location, and duodenum mucosa chromogranin-A is a potential biomarker with increased expression in an age-matched manner.
- Open Access
- 7 February 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (2) , 87
Pancreatic Fibrosis and Chronic Pancreatitis: Mini-Review of Non-Histologic Diagnosis for Clinical Applications
Pancreatic fibrosis is the dominant reversible pathological change and diagnostic factor in early chronic pancreatitis, defined by a mechanistic approach proposed in 2016. Main guidelines for chronic pancreatitis were published by the American Pancreas Association in 2014, the Japanese Society of Gastroenterology in 2015, and United European Gastroenterology in 2017. All three sets of guidelines mentioned that the staging of chronic pancreatitis is important but challenging. There are various image modalities for the non-histologic diagnosis of pancreatic fibrosis: (1) shear wave elastography, such as an acoustic radiation force impulse with a cut-off value of 1.4 m/s; (2) strain elastography using grades of strain; (3) endoscopic ultrasonography using the Rosemont criteria or endoscopic ultrasound criteria for early chronic pancreatitis proposed by the Japan Pancreas Society; (4) computed tomography using the Hounsfield scale or number of micro-calcifications; and (5) magnetic resonance imaging using the apparent diffusion coefficient and the T1w flash and T2w HASTE sequences. The clinical applications are to (1) evaluate pancreatic tumors and inflammatory disease; (2) monitor dyspepsia with early chronic pancreatitis; (3) monitor individuals with a high risk of pancreatic cancer; (4) analyze a fatty pancreas with fibrosis; (5) predict a fistula after pancreatic surgery; and (6) predict outcomes for chronic pancreatitis or pancreatic cancer. The selection of tools will be dependent on the clinical scenario. Conclusion: There are various modalities for the non-histologic diagnosis of pancreatic fibrosis. The selection of the optimal device will be dependent on the clinical scenario.
- 7 February 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (2) , 87
Open AccessPancreatic Fibrosis and Chronic Pancreatitis: Mini-Review of Non-Histologic Diagnosis for Clinical Applications
Pancreatic fibrosis is the dominant reversible pathological change and diagnostic factor in early chronic pancreatitis, defined by a mechanistic approach proposed in 2016. Main guidelines for chronic pancreatitis were published by the American Pancreas Association in 2014, the Japanese Society of Gastroenterology in 2015, and United European Gastroenterology in 2017. All three sets of guidelines mentioned that the staging of chronic pancreatitis is important but challenging. There are various image modalities for the non-histologic diagnosis of pancreatic fibrosis: (1) shear wave elastography, such as an acoustic radiation force impulse with a cut-off value of 1.4 m/s; (2) strain elastography using grades of strain; (3) endoscopic ultrasonography using the Rosemont criteria or endoscopic ultrasound criteria for early chronic pancreatitis proposed by the Japan Pancreas Society; (4) computed tomography using the Hounsfield scale or number of micro-calcifications; and (5) magnetic resonance imaging using the apparent diffusion coefficient and the T1w flash and T2w HASTE sequences. The clinical applications are to (1) evaluate pancreatic tumors and inflammatory disease; (2) monitor dyspepsia with early chronic pancreatitis; (3) monitor individuals with a high risk of pancreatic cancer; (4) analyze a fatty pancreas with fibrosis; (5) predict a fistula after pancreatic surgery; and (6) predict outcomes for chronic pancreatitis or pancreatic cancer. The selection of tools will be dependent on the clinical scenario. Conclusion: There are various modalities for the non-histologic diagnosis of pancreatic fibrosis. The selection of the optimal device will be dependent on the clinical scenario.